Evaluation of a Live Attenuated Recombinant Virus RAV 9395 as a Herpes Simplex Virus Type 2 Vaccine in Guinea Pigs

Recombinant virus RAV 9395 was constructed by deleting both copies of the γ134.5 gene, and the UL55 and UL56 open reading frames from herpes simplex virus type 2 (HSV-2) strain G. The potential use of RAV 9395 as an HSV-2 vaccine was investigated by evaluating the ability of RAV 9395 to protect guin...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infectious diseases Vol. 177; no. 5; pp. 1143 - 1154
Main Authors:	Spector, Frances C., Kern, Earl R., Palmer, Joyce, Kaiwar, Ravi, Cha, Tai-An, Brown, Peter, Spaete, Richard R.
Format:	Journal Article
Language:	English
Published:	Chicago, IL The University of Chicago Press 01-05-1998 University of Chicago Press
Subjects:	Animals Biological and medical sciences Cell Line Cercopithecus aethiops DNA, Viral - analysis Dosage Female Fundamental and applied biological sciences. Psychology Gene Deletion Genitalia Genome, Viral Genotype Guinea Pigs Herpes Genitalis - immunology Herpes Genitalis - prevention & control Herpesvirus 2, Human - genetics Herpesvirus 2, Human - immunology Herpesvirus 2, Human - isolation & purification Human herpesvirus 1 Human herpesvirus 2 Humans Infections Kidney Lesions Major Articles Microbiology Open Reading Frames Phenotype Rabbits Simplexvirus Transcriptional regulatory elements Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Attenuated Vaccines, Synthetic Vero Cells Viral Vaccines Virology Viruses Immunoprotection Immunization Recombinant virus Herpesviridae Alphaherpesvirinae Rodentia Vaccine Virus Vertebrata Mammalia Guinea pig Efficiency Herpesvirus hominis 2 Animal Attenuated strain
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Recombinant virus RAV 9395 was constructed by deleting both copies of the γ134.5 gene, and the UL55 and UL56 open reading frames from herpes simplex virus type 2 (HSV-2) strain G. The potential use of RAV 9395 as an HSV-2 vaccine was investigated by evaluating the ability of RAV 9395 to protect guinea pigs from severe disease by HSV-2(G) challenge. RAV 9395 administered intramuscularly reduced both lesion development and severity in a dose-dependent manner in guinea pigs challenged with HSV-2(G). The frequency of reactivation of RAV 9395 from explanted dorsal root ganglia was low compared with that of HSV-2(G). Immunization with RAV 9395 at doses of 1 × 105 pfu and above generally precluded the establishment of latency by the challenge virus. The results presented in this report lend support for the development of genetically engineered live HSV vaccines.
Bibliography:	Present affiliation: Avigen, Alameda, California. istex:CD72056F24BF41155C10FCF36FDDB39E57BFCF59 ark:/67375/HXZ-G5CLJPDJ-C ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0022-1899 1537-6613
DOI:	10.1086/515278